186 related articles for article (PubMed ID: 12912933)
1. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
Santini D; Vincenzi B; Dicuonzo G; Avvisati G; Massacesi C; Battistoni F; Gavasci M; Rocci L; Tirindelli MC; Altomare V; Tocchini M; Bonsignori M; Tonini G
Clin Cancer Res; 2003 Aug; 9(8):2893-7. PubMed ID: 12912933
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
[TBL] [Abstract][Full Text] [Related]
3. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
[TBL] [Abstract][Full Text] [Related]
5. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Santini D; Vincenzi B; Hannon RA; Brown JE; Dicuonzo G; Angeletti S; La Cesa A; Coleman RE; Tonini G; Budillon A; Caraglia M; Holen I
Oncol Rep; 2006 May; 15(5):1351-7. PubMed ID: 16596210
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
Santini D; Vincenzi B; Avvisati G; Dicuonzo G; Battistoni F; Gavasci M; Salerno A; Denaro V; Tonini G
Clin Cancer Res; 2002 May; 8(5):1080-4. PubMed ID: 12006522
[TBL] [Abstract][Full Text] [Related]
7. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
Dicuonzo G; Vincenzi B; Santini D; Avvisati G; Rocci L; Battistoni F; Gavasci M; Borzomati D; Coppola R; Tonini G
J Interferon Cytokine Res; 2003 Nov; 23(11):649-54. PubMed ID: 14651779
[TBL] [Abstract][Full Text] [Related]
8. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2008; 25(3):346-9. PubMed ID: 18204821
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
Amir E; Trinkaus M; Simmons CE; Dranitsaris G; Clemons MJ
J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
[TBL] [Abstract][Full Text] [Related]
10. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
[TBL] [Abstract][Full Text] [Related]
11. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
[TBL] [Abstract][Full Text] [Related]
12. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
Chen T; Berenson J; Vescio R; Swift R; Gilchick A; Goodin S; LoRusso P; Ma P; Ravera C; Deckert F; Schran H; Seaman J; Skerjanec A
J Clin Pharmacol; 2002 Nov; 42(11):1228-36. PubMed ID: 12412821
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting.
Santini D; Zoccoli A; Gregorj C; Di Cerbo M; Iuliani M; Pantano F; Zamarchi R; Sergi F; Flammia G; Buscarini M; Rizzo S; Cicero G; Russo A; Vincenzi B; Avvisati G; Tonini G
Oncology; 2013; 85(6):342-7. PubMed ID: 24335337
[TBL] [Abstract][Full Text] [Related]
15. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts.
Zafar S; Coates DE; Cullinan MP; Drummond BK; Milne T; Seymour GJ
J Oral Pathol Med; 2014 Oct; 43(9):711-21. PubMed ID: 24762323
[TBL] [Abstract][Full Text] [Related]
19. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
20. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
